Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B
- PMID: 29599296
- PMCID: PMC5961397
- DOI: 10.2337/dc18-0040
Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B
Abstract
Objective: Metabolic syndrome (MS) is prevalent and is associated with adverse outcomes of liver disease. We evaluated the prevalence of MS and its influence on alanine aminotransferase (ALT) levels and fibrosis, as estimated by the aspartate aminotransferase-to-platelet ratio index (APRI), in a large, multiethnic North American cohort with chronic hepatitis B (HBV) infection.
Research design and methods: Adults with chronic HBV from 21 centers within the U.S. and Canada were evaluated at baseline and for up to 5 years (median 3.7 years) of follow-up. MS was defined as the presence of at least three of five criteria including waist circumference, blood pressure, glucose, triglyceride, and HDL levels.
Results: Analysis included 777 participants, of whom 171 (22%) had MS. Participants with MS (vs. those without MS) were older (median age 54.4 vs. 40.2 years), more often male (61% vs. 51%), and born in the U.S./Canada or had immigrated >20 years ago (60% vs. 43%). MS was not associated with ALT or APRI at baseline. Upon adjusted multivariable analysis of serial ALT values, ALT was significantly higher (mean 12%; P = 0.02) among those with MS at baseline and even higher (mean 19%; P = 0.003) among those with persistent MS compared with those with persistent absence of MS. MS was not associated with serial APRI on follow-up.
Conclusions: MS was prevalent in this HBV cohort and was independently associated with higher ALT levels longitudinally. These findings highlight the importance of screening for MS and the potential for MS to influence ALT and its interpretation in the context of HBV treatment decisions.
Trial registration: ClinicalTrials.gov NCT01263587.
© 2018 by the American Diabetes Association.
Figures
References
-
- Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546–1555 - PubMed
-
- Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012;56:422–433 - PubMed
-
- McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am 2014;98:39–54 - PubMed
-
- Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410–1415 - PubMed
-
- Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645 - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U01 DK082944/DK/NIDDK NIH HHS/United States
- U01 DK082872/DK/NIDDK NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- P30 DK050306/DK/NIDDK NIH HHS/United States
- U01 DK082943/DK/NIDDK NIH HHS/United States
- U01 DK082874/DK/NIDDK NIH HHS/United States
- K24 AA022523/AA/NIAAA NIH HHS/United States
- M01 RR000040/RR/NCRR NIH HHS/United States
- UL1 TR001111/TR/NCATS NIH HHS/United States
- U01 DK082864/DK/NIDDK NIH HHS/United States
- U01 DK082866/DK/NIDDK NIH HHS/United States
- UL1 TR002240/TR/NCATS NIH HHS/United States
- U01 DK082923/DK/NIDDK NIH HHS/United States
- U01 DK082863/DK/NIDDK NIH HHS/United States
- UL1 TR000058/TR/NCATS NIH HHS/United States
- U01 DK082843/DK/NIDDK NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- U01 DK082867/DK/NIDDK NIH HHS/United States
- U01 DK082919/DK/NIDDK NIH HHS/United States
- U01 DK082927/DK/NIDDK NIH HHS/United States
- U01 DK082871/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
